**2. Drug repositioning strategy**

During preliminary screening on Drug, many possibilities of drug repurposing may arise by chance and later based on proper justification few of them have been tested for alternate application in another disease that called as shifting from bench to bedside. Oppositely, it may happen that unpredicted results of clinical trials suggest ideas for drug repurposing and later same things justified by scientific experiments that called as bedside to bench. According to FDA approved drug database, around 80–90% of drug gets failed in clinical trials due to various reasons and one of the majors is that the lack of efficacy during phase- III of clinical trial. That failure rate figures out around 30–50% and all these drugs might be good candidate for repurposing. The **Figure 2** indicate different approaches that begin with constructing hypothesis based on existing fund of knowledge to expanding its *in silico* frame work for preliminary testing and later on validating facts based on more vigorous and stringent analysis like preclinical and clinical studies [10].

**Figure 2.** *Various approaches of drug repurposing.*
